Per Malmström

4.1k total citations
61 papers, 2.6k citations indexed

About

Per Malmström is a scholar working on Cancer Research, Oncology and Molecular Biology. According to data from OpenAlex, Per Malmström has authored 61 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 42 papers in Cancer Research, 38 papers in Oncology and 13 papers in Molecular Biology. Recurrent topics in Per Malmström's work include Breast Cancer Treatment Studies (36 papers), HER2/EGFR in Cancer Research (12 papers) and Breast Lesions and Carcinomas (12 papers). Per Malmström is often cited by papers focused on Breast Cancer Treatment Studies (36 papers), HER2/EGFR in Cancer Research (12 papers) and Breast Lesions and Carcinomas (12 papers). Per Malmström collaborates with scholars based in Sweden, United States and Finland. Per Malmström's co-authors include Mårten Fernö, Pär‐Ola Bendahl, Jorma Isola, Sofia K. Gruvberger-Saal, Jonas Bergh, Åke Borg, Lao H. Saal, Dorthe Grabau, Martin Sjöström and Carl Blomqvist and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Lancet and Journal of Clinical Oncology.

In The Last Decade

Per Malmström

61 papers receiving 2.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Per Malmström Sweden	26	1.3k	1.1k	1.0k	515	386	61	2.6k
Florence Lerebours France	29	1.4k 1.1×	1.2k 1.1×	915 0.9×	692 1.3×	248 0.6×	97	2.6k
Melanie Royce United States	30	1.8k 1.4×	1.2k 1.1×	978 1.0×	700 1.4×	309 0.8×	93	3.1k
Alberto Bottini Italy	32	1.6k 1.2×	1.5k 1.4×	1.1k 1.1×	510 1.0×	295 0.8×	117	3.1k
Mónica Arnedos France	25	1.6k 1.2×	1.2k 1.1×	1.4k 1.4×	1.0k 2.0×	266 0.7×	90	3.1k
Dorthe Grabau Sweden	28	1.5k 1.1×	1.6k 1.5×	1.3k 1.3×	510 1.0×	389 1.0×	57	3.0k
Gina G. Chung United States	25	1.5k 1.2×	911 0.8×	1.3k 1.3×	510 1.0×	224 0.6×	68	3.2k
Jeremy Braybrooke United Kingdom	23	1.4k 1.0×	979 0.9×	1.0k 1.0×	674 1.3×	383 1.0×	64	2.9k
Thomas Bachelot France	28	1.5k 1.2×	858 0.8×	1.0k 1.0×	855 1.7×	243 0.6×	130	3.0k
Sami Diab United States	27	1.8k 1.3×	1.0k 0.9×	812 0.8×	805 1.6×	386 1.0×	74	2.8k
Anne Hansen Ree Norway	30	1.3k 1.0×	661 0.6×	1.2k 1.2×	506 1.0×	290 0.8×	139	3.2k

Countries citing papers authored by Per Malmström

Since Specialization

Citations

This map shows the geographic impact of Per Malmström's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Per Malmström with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Per Malmström more than expected).

Fields of papers citing papers by Per Malmström

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Per Malmström. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Per Malmström. The network helps show where Per Malmström may publish in the future.

Co-authorship network of co-authors of Per Malmström

This figure shows the co-authorship network connecting the top 25 collaborators of Per Malmström. A scholar is included among the top collaborators of Per Malmström based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Per Malmström. Per Malmström is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Sjöström, Martin, Anthony Fyles, Fei‐Fei Liu, et al.. (2023). Development and Validation of a Genomic Profile for the Omission of Local Adjuvant Radiation in Breast Cancer. Journal of Clinical Oncology. 41(8). 1533–1540. 21 indexed citations

Nordenskjöld, Anna, Helena Fohlin, Johan Rosell, et al.. (2023). Breast cancer survival and incidence of second primary cancers after 30 years in a randomized study of two versus five years of adjuvant tamoxifen therapy. The Breast. 71. 63–68. 2 indexed citations

Sjöström, Martin, Erik Holmberg, Per Karlsson, et al.. (2022). Breast cancer hypoxia in relation to prognosis and benefit from radiotherapy after breast-conserving surgery in a large, randomised trial with long-term follow-up. British Journal of Cancer. 126(8). 1145–1156. 34 indexed citations

Bendahl, Pär‐Ola, et al.. (2021). High CYP27A1 expression is a biomarker of favorable prognosis in premenopausal patients with estrogen receptor positive primary breast cancer. npj Breast Cancer. 7(1). 127–127. 11 indexed citations

Killander, Fredrika, Elinore Wieslander, Per Karlsson, et al.. (2020). No Increased Cardiac Mortality or Morbidity of Radiation Therapy in Breast Cancer Patients After Breast-Conserving Surgery: 20-Year Follow-up of the Randomized SweBCGRT Trial. International Journal of Radiation Oncology*Biology*Physics. 107(4). 701–709. 16 indexed citations

Sjöström, Martin, S. Laura Chang, Nick Fishbane, et al.. (2019). Comprehensive Transcriptomic Profiling Identifies Breast Cancer Patients Who May Be Spared Adjuvant Systemic Therapy. Clinical Cancer Research. 26(1). 171–182. 12 indexed citations

Matikas, Alexios, Sara Margolin, Mats Hellström, et al.. (2017). Long-term safety and survival outcomes from the Scandinavian Breast Group 2004-1 randomized phase II trial of tailored dose-dense adjuvant chemotherapy for early breast cancer. Breast Cancer Research and Treatment. 168(2). 349–355. 7 indexed citations

Ehinger, Anna, Pär‐Ola Bendahl, C.W. Elston, et al.. (2014). The role of histological grade in discrimination between Luminal A-like and Luminal B-like subtypes in a series of premenopausal breast cancer patients. Lund University Publications (Lund University). 2 indexed citations

Killander, Fredrika, Harald Anderson, Elisabeth Kjellén, & Per Malmström. (2014). Increased cardio and cerebrovascular mortality in breast cancer patients treated with postmastectomy radiotherapy – 25 year follow-up of a randomised trial from the South Sweden Breast Cancer Group. European Journal of Cancer. 50(13). 2201–2210. 22 indexed citations

10.

Broselid, Stefan, Benxu Cheng, Martin Sjöström, et al.. (2013). G Protein–Coupled Estrogen Receptor Is Apoptotic and Correlates with Increased Distant Disease-Free Survival of Estrogen Receptor–Positive Breast Cancer Patients. Clinical Cancer Research. 19(7). 1681–1692. 35 indexed citations

11.

Klintman, Marie, Carina Strand, Cecilia Ahlin, et al.. (2013). The Prognostic Value of Mitotic Activity Index (MAI), Phosphohistone H3 (PPH3), Cyclin B1, Cyclin A, and Ki67, Alone and in Combinations, in Node-Negative Premenopausal Breast Cancer. PLoS ONE. 8(12). e81902–e81902. 24 indexed citations

12.

Kimbung, Siker, Anikó Kovács, Pär‐Ola Bendahl, et al.. (2013). Claudin‐2 is an independent negative prognostic factor in breast cancer and specifically predicts early liver recurrences. Molecular Oncology. 8(1). 119–128. 47 indexed citations

13.

Gruvberger-Saal, Sofia K., Pär‐Ola Bendahl, Lao H. Saal, et al.. (2007). Estrogen Receptor β Expression Is Associated with Tamoxifen Response in ERα-Negative Breast Carcinoma. Clinical Cancer Research. 13(7). 1987–1994. 154 indexed citations

14.

Killander, Fredrika, Harald Anderson, Stefan Rydén, et al.. (2007). Radiotherapy and tamoxifen after mastectomy in postmenopausal women – 20 year follow-up of the South Sweden Breast Cancer group randomised trial SSBCG II:I. European Journal of Cancer. 43(14). 2100–2108. 19 indexed citations

15.

Luoma, Minna‐Liisa, Liisa Hakamies‐Blomqvist, Johanna Sjöström, et al.. (2002). Physical Performance, Toxicity, and Quality of Life as Assessed by the Physician and the Patient. Acta Oncologica. 41(1). 44–49. 13 indexed citations

16.

Bergh, Jonas, Tom Wiklund, Björn Erikstein, et al.. (2000). Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial. The Lancet. 356(9239). 1384–1391. 217 indexed citations

17.

Hakamies‐Blomqvist, Liisa, Minna‐Liisa Luoma, J Sjöström, et al.. (2000). Quality of life in patients with metastatic breast cancer receiving either docetaxel or sequential methotrexate and 5-fluorouracil. A multicentre randomised phase III trial by the Scandinavian Breast Group. European Journal of Cancer. 36(11). 1411–1417. 38 indexed citations

18.

Lilja, Åsa, Gudmund J. W. Smith, Per Malmström, Leif G. Salford, & Ingrid Idvall. (1998). Psychological profile related to malignant tumours of different histopathology. Psycho-Oncology. 7(5). 376–386. 8 indexed citations

19.

Strömblad, Lars-Göran, Harald Anderson, Per Malmström, & Leif G. Salford. (1993). Reoperation for malignant astrocytomas: Personal experience and a review of the literature. British Journal of Neurosurgery. 7(6). 623–633. 18 indexed citations

20.

Sandberg‐Wollheim, Magnhild, K Hougaard, Per Malmström, et al.. (1991). A randomized study of chemotherapy with procarbazine, vincristine, and lomustine with and without radiation therapy for astrocytoma grades 3 and/or 4. Cancer. 68(1). 22–29. 97 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact